Skip to main content
. 2020 Mar 13;19:100159. doi: 10.1016/j.jctube.2020.100159

Table 1.

MTBC positivity and RR tested in sputum samples from new suspected MDR-PTB cases using Xpert MTB/RIF during 2016–2018.

Total sputum samples Xpert MTB/RIF
3009 MTBC Pos (1181/3009, 39.25%)
RS RR
1090/3009 (36.22%) 91/3009 (3.02%)

RS: Rifampicin sensitive; RR: Rifampicin resistant.